
IRISH JOURNAL OF **PSYCHOLOGICAL** MOL 16 NO 2 JUNE 1999 MEDICINE ISSN 0700-9067



"Straight and Narrow" by Janet Mullarney, 1991 (Painted wood, 208 x 320 x 137cm) From the Collection at the Irish Museum of Modern Art, Royal Hospital Kilmainham, Dublin 8. "The Straight and Narrow is to do with the Catholic idea of sacrificing. My personal guardian angel was repressive...The work is to do with the releasing of inhibitions." (Janet Mullarney)



Add life to living with schizophrenia

Solian is a new benzamide antipsychotic, with the ability to treat both the positive¹ and negative² symptoms of schizophrenia.

Solian offers a lower incidence of EPS than standard neuroleptics such as haloperidol,³ as well as avoiding some of the drawbacks of certain atypicals: it does not require routine cardiovascular⁴ or haematological^{4,5}

monitoring and patients gain significantly less weight than those treated with risperidone.²

So when patients need the ability to cope with their condition, Solian has the power to treat their positive¹ and their negative² symptoms whilst still allowing them to do the everyday things that the rest of us tal for granted.



Efficacy that patients can live with

Solian 50 and 200 amisulpride.

Prescribing Information. Presentation: Solian 200 tablets contain 200 mg amisulpride and Solian 50 tablets contain 50 mg amisulpride. Indication: Acute and chronic schizophrenia including predominant negative symptoms. Dosage: Acute psychotic episodes: 400-800 mg/day. Doses above 800 mg/day have not demonstrated greater efficacy but have increased rates of extrapyramidal symptoms. Dose titration not required on initiation of therapy; adjust dose according to individual response. For patients with mixed positive and negative symptoms, adjust dose for optimal control of positive symptoms. Amisulpride should be administered bd for doses above 400 mg. Establish maintenance treatment individually with the minimal effective dose. Predominant negative symptoms: 50-300 mg once daily adjusted according to individual response. Elderly: administer with caution due to the risk of hypotension or sedation. Children: contraindicated in children up to puberty (safety not established). Renal insufficiency: Reduce dose to half in patients with creatinine clearance between 10-30 ml/min. Hepatic insufficiency: no dosage adjustment necessary. Contraindications: Hypersensitivity, concomitant prolactin-dependent tumours e.g. pituitary gland prolactinomas and breast cancer, phaeochromocytoma; children up to puberty; lactation. Warning and Precautions: As with all neuroleptics, neuroleptic hmalignant syndrome may occur (discontinue/Solian) a Gaetip Campadgents with a Ristory of epilepsy and Parkinson's disease. Not recommended for use in pregnancy unless benefits outweigh risks. Interactions: Caution in concomitant administration of CNS depressants (including alcohol), antihypertensives and other hypotensive medications, and dopamine agonists. Side Effects: Insomnia, anxiety, agitation. Less commonly somnolence and Gl disorders. In common with other neuroleptics Solian causes a reversible increase in plasma prolactin levels. Solian may also cause weight gain, acute dystonia, extrapyramidal symptoms, tardive dyskinesia, hypotension and bradycardia. Rarely, allergic reactions, seizures and neuroleptic malignant syndrome have been reported. Cost: Blister packs of : 200 mg x 60 tablets £67.94: 50 mg x 60 tablets £18.61. Legal Category: POM. Marketing Authorisation Numbers: Solian 50 - PA 832/4/2; Solian 200 - PA 832/4/3. Marketing Authorisation Holder: Lorex Synthélabo UK & Ireland Ltd, Foundation Park, Roxborough Way, Maidenhead, Berks SL6 3UD. Further information is available from the Marketing Authorisation Holder. Irish Distributor: Allphar Services, Dublin. Tel: (01) 404 1600. References: 1. Freeman HL. Int Clin Psychopharmacol 1997;12(Suppl 2):S11-S17. 2. Möller HJ. 6th World Congress of Biological Psychiatry, Nice, France.

June 22-27 1997. 3. Coukell AJ, Spencer CM, Benfield P. CNS Drugs (Adis) 1996 Sep 6 (3):237-256. 4. Solian SPC. Lorex Synthélabo. 5. Clozapine SPC. Novartis. **Date of preparation:** May 1999.



Editor-in-Chief: Brian Lawlor

Editorial Co-ordinator: Niamh Gleeson

Editorial Assistant: Anne Henrichsen

Advertising Manager: Mary Kate O'Flanagan

Founding Editor: Mark Hartman

Editors: Timothy Dinan (London), David King (Belfast)

Deputy Editor: Brian O'Shea (Dublin)

Associate Editors: Ken Brown (Belfast), Patricia Casey (Dublin), Anthony Clare (Dublin), Stephen Cooper (Belfast), Thomas Fahy (Galway), Michael Fitzgerald (Dublin), Michael Kelleher (Cork), Brian Leonard (Galway), Roy McClelland (Belfast), Aidan McGennis (Dublin), Ciaran O'Boyle (Dublin), Eadbhard O'Callaghan (Dublin), Art O'Connor (Dublin), Ethna O'Gorman (Belfast), Ian Pullen (Edinburgh), David Sheehan (Tampa), Philip Snaith (Leeds), Hugh Staunton (Dublin), John Waddington (Dublin), Richard Williams (Calgary)

Statistical Editor: Leslie Daly (Dublin)

Deputy Statistical Editor:

Ronan Conroy (Dublin)

Submissions & correspondence to: The Editor,

Irish Journal of Psychological Medicine, 25 Adelaide Street, Dun Laoghaire, Co Dublin.

Telephone

01-2803967; Int: +353-1-2803967 Fax

01-2807076; Int: +353-1-2807076

Publisher MedMedia Ltd. Media House, 25 Adelaide Street, Dun Laoghaire, Co Dublin.

Printing: New Cityview Press

Subscriptions

Rates per volume of four issues (Mar, Jun, Sept, Dec) sTG£43 EU, US\$96 USA, sTG£53 elsewhere (single issues US\$28 USA, sTG£13.25 elsewhere) incl. airmail postage internationally.

Subscription enquiries, orders and cheques made payable to:

Royal Society of Medicine Press Ltd., 1 Wimpole St, London, W1M 8AE, UK. Tel: 0171-2902927; int: +44-171-2902927. Fax: 0171-2902929; int: +44-171-2902929.

Circulation

3,000 to 54 countries. Journal participates in the World Health Organisation project to improve distribution of scientific materials on mental health. Publication does not imply endorsement. Limited photocopying authorisation granted for a fee to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA, or to appropriate Reproduction Rights Organisation; isolated non-profit, academic photocopying excepted.

IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

VOL 16 NO 2 JUNE 1999 ISSN 0790-9667

EDITORIAL

41 Consultant psychotherapists: who needs them? Clare Adams & Maria O'Kane

ORIGINAL PAPERS

- **43** The utility of naming tests in the diagnosis of Alzheimer's disease Robert F Coen, Nicholas Kidd, Aisling Denihan, Conal Cunningham, Irene Bruce, Fiona Buggy, Desmond O'Neill, J Bernard Walsh, Davis Coakley & Brian A Lawlor
- 46 Health gain for epilepsy associated with learning disabilities psychiatric care Elizabeth Beber, Nicola M Bailey & Sally-Ann Cooper
- 51 Criminal responsibility and mental illness in Ireland 1850-1995: fitness to plead

Pat Gibbons, Niamh Mulryan, Angela McAleer & Art O'Connor

BRIEF REPORTS

- 57 Empirical investigation into placebo effectiveness Barbara Dolinska
- 59 Personality traits in parents of people with autism Susan O'Hanrahan, Michael Fitzgerald & Myra O'Regan
- 61 Deliberate self-harm: how feasible are the current guidelines? Alan Currie & Richard Blennerhassett
- 64 Depot antipsychotic prophylaxis in bipolar affective disorder L Mannion, PA Carney, D Sloan & R O'Toole

AUDITS

67 Management advice for children with chronic fatigue syndrome: a systematic study of information from the internet Barry Wright, Christine Williams & Ian Partridge

CASE REPORTS

72 Suicidal behaviour - does it exist in pre-school aged children? Louise Connolly

56 Guidelines for authors

69a John Dunne Medal

- 75 Letters to the Editor
- 77 Book Reviews

Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE/INIST: PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT
CONTENTS/ Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS
(PsycINFO/PsycLIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International
Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts),
Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.
Microfilm, microfiche & article copies from University Microfilms International , 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the Adonis service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in Ulrich's
International Periodicals Directory (Bowker International Serials Database), EBSCO's Selected Periodicals for the Medical and Health
Sciences, & EBSCO's Librarians' Handbook,









Abbreviated Prescribing Information: LUSTRAL™ (sertraline) Presentation: Tablets containing 50mg or

Presentation: Tablets containing 50mg or 100mg sertraine. Indications: Treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. Obsessive compulsive disorder (OCD). Dosage: Lustral should be given as a single daily dose. The initial dose is 50mg and the usual antidepressant dose is 50mg. Dosage can be further increased, if appropriate, to a maximum of 200mg daily. Patients should be maintained on the lowest effective dose. Use in children: Not recommended. Use in delerv: Usual adult dose. Contra-indications:

recommended. Use in elderly: Usual adult dose. Contra-indications: Hypersensitivity to this group of drugs. Hepatic insufficiency, unstable epileosyand convulsant disorders, pregnano and lactationar Do not use with, or within two weeks of ending treatment with https

MAOI's. At least 14 days should elapse before starting any MAOI following discontinuation of Lustral. **Precautions, warnings:** Renal insufficiency, ECT, epilepsy, driving. Lustral should be discontinued in a patient who develops seizures. Lustral should not be administered with benzodiazepines or other tranquillizers in patient; when develops a machines; The patient should not be administered with benzodiazepines or other tranquilizers in patients who drive or operate machinery. The patient should be monitored for signs of suicide or mania. **Drug Interactions:** Caution with other centrally active medication. Serotonergic drugs such as tryptophan or fenfluramine should not be used with Lustral. Lithium levels should be monitored. Although Lustral has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential drug drugs drug drugs with context with other highly protein bound drugs concomitant use with alconol is not recommended. The potential for Lustral to interact with other highly protein bound drugs should be borne in mind. Interactions with e.g. warfarin, diazepam, tolbutamide and cimetidine have not been fully assessed. With warfarin prothrombin time should be monitored whenge unstrain the initiated or stopped. **Side-Effects:** Dry mouth, nausea, diarrhoea/loose stools, ejaculatory delay, tremor, increased sweating, dizziness, insomnia, somnolence, headache and dyspepsia. Rarely, abnormal LFTs, hyponatraemia. The following have been reported with Lustral but may have no casual relationship: movement disorders, convulsions, menstrual irregularities, hyperprolactinaemia, galactorrhoea and rash. As with other serotonin re-uptake inhibitors rare reports of agitation, confusion, depersonalisation, hallucinations, nervousness, postural hypotension, hypo/hypertension, tachycardia and arrhythmias. As with all psychoactive medicines, possible side effects on discontinuation, such as dizziness, sensory disturbance, sleep disturbance, agitation or anxiety, nausea and sweating. Legal Category: 51A. Package Quantities: 50mg tablet (PA 822/1/s) Calendar pack of 28; 100mg tablet (PA 822/1/5) Calendar pack of 28. Product Authorisation Holder: Pfizer (Ireland) Limited, Pharmapark, Chapelizod, Dublin 20, Republic of Ireland. Further information on request: Pfizer (Ireland) Limited. Date last revised: 1/11/96 66973 June 97

66973 June 97

